ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0978 • ACR Convergence 2024

    Associations of Fire Smoke and Other Pollutants with Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Vanessa Kronzer1, Yangyuna Yang2, Punyasha Roul3, James Crooks4, Cynthia Crowson1, John Davis1, Jeffrey Sparks5, Jeffrey Pierce6, Katelyn O'Dell7, Sauer brian8, grant Cannon9, Joshua Baker10, Ted Mikuls2 and Bryant England2, 1Mayo Clinic, Rochester, MN, 2University of Nebraska Medical Center, Omaha, NE, 3UNMC, Omaha, NE, 4National Jewish Health, Denver, 5Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 6Colorado State University, Fort Collins, 7George Washington University, Washington DC, 8Salt Lake City VA/University of Utah, Salt Lake City, UT, 9University of Utah and Salt Lake City VA, Salt Lake City, UT, 10Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Wildfires have burned increasing acreage in the United States (US) since the 1980s, releasing record and alarming levels of particulate matter smaller than 2.5…
  • Abstract Number: 1036 • ACR Convergence 2024

    A Pilot Trial of Integrating Patient-Reported Outcome Measurement Information System (PROMIS®) into Rheumatology Care

    Rosemary Gedert1, Danielle Ochocki1, Neda Kortam1, Suiyuan Huang1, Vivek Nagaraja2, Katherine Chakrabarti1, Julia Ford1, Martin Garber1, Jiha Lee1, Vladimir Ognenovski1, David Roofeh3, David Cella4 and Dinesh Khanna1, 1University of Michigan, Ann Arbor, MI, 2Mayo Clinic Arizona, Scottsdale, AZ, 3Rutgers-RWJ Medical School, New Brunswick, NJ, 4Northwestern University, Chicago, IL

    Background/Purpose: Utilizing Patient-Reported Outcomes Measurement Information System (PROMIS®) questionnaires can enhance clinical care by measuring longitudinal changes in symptom severity as reported by the patient.…
  • Abstract Number: 1228 • ACR Convergence 2024

    Central Pain Mechanisms and Physical Function in Early Rheumatoid Arthritis

    Burcu Aydemir1, Lutfiyya Muhammad2, Jing Song3, Dorothy Dunlop4, Kathleen Aren5, Mary Carns5, Wendy Marder6, Vivian Bykerk7, Kevin Deane8, Clifton Bingham9 and Yvonne Lee1, 1Northwestern University, Chicago, IL, 2Northwestern Feinberg School of Medicine, Chicago, IL, 3Northwestern University, Worthington, MN, 4Northwestern University, New Haven, CT, 5Northwestern University Division of Rheumatology, Chicago, IL, 6University of Michigan, Ann Arbor, MI, 7Hospital For Special Surgery, New York, NY, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9Johns Hopkins University, Baltimore, MD

    Background/Purpose: Despite effective control of inflammation, patients with rheumatoid arthritis (RA) may experience lingering pain and losses in physical function. Pain can occur because central…
  • Abstract Number: 1335 • ACR Convergence 2024

    The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA

    Charis Meng1, Margaret Butler1, Deanna Jannat-Khah1, Yvonne Lee2, Clifton Bingham3 and Vivian Bykerk1, 1Hospital for Special Surgery, New York, NY, 2Northwestern University, Chicago, IL, 3Johns Hopkins University, Baltimore, MD

    Background/Purpose: Non-articular pain (NAP) is often reported by early RA (eRA) patients, impacts RA remission (REM) but remains poorly defined and this hampers RA care.…
  • Abstract Number: 1351 • ACR Convergence 2024

    Development of Noninvasive Assessment Technology for Rheumatoid Arthritis Based on Contact Property Measurements

    Woo-Joong KIM1, Chanseok PARK2, Seungmo KOO2, Jae-Young CHEONG2 and Jiho KIM2, 1Chung-Ang University Hospital, Seoul, Korea, Seoul, Republic of Korea, 2Hongik University, Seoul, Korea, Seoul, Republic of Korea

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that requires regular monitoring to prevent joint damage and systemic complications. However, the shortage of trained…
  • Abstract Number: 1367 • ACR Convergence 2024

    Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY

    James Galloway1, Jérôme Avouac2, Gerd Burmester3, Roberto Caporali4, Thomas P.A. Debray5, Katrien Van Beneden6, Neil Betteridge7, Susana Romero Yuste8, Monia Zignani5, Patrick Verschueren9 and Karen Bevers10, 1Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 2Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 3Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 4Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 5Alfasigma S.p.A., Bologna, Italy, 6Medical Affairs, Galapagos NV, Mechelen, Belgium, 7Neil Betteridge Associates, Lonodn, United Kingdom, 8Department of Rheumatology, University Hospital Complex of Pontevedra, Pontevedra, Spain, 9Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, 10Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands

    Background/Purpose: FILOSOPHY (NCT04871919) and PARROTFISH (NCT05323591) are ongoing, prospective, observational Phase 4 studies of filgotinib in patients with RA. This interim analysis evaluated effectiveness and…
  • Abstract Number: 1384 • ACR Convergence 2024

    Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Qianru Zhang1, Gregory McDermott2, Sung Hae Chang3, Pierre-Antoine Juge4, Kathleen Vanni5, Grace Qian6, Katarina Bade5, Kevin Mueller5, Emily Kowalski5, Alene Saavedra5 and Jeffrey Sparks7, 1Harard Medical School, Cambridge, 2Brigham and Women's Hospital, Brookline, MA, 3Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, 4Service de Rhumatologie, Hôpital Bichat - Claude-Bernard, AP-HP, Paris, Île-de-France, France, PARIS, Germany, 5Brigham and Women's Hospital, Boston, MA, 6Brigham and Women’s Hospital, Boston, MA, 7Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a serious extra-articular manifestation of RA, affecting 7-12% of patients and associated with three-fold increased mortality compared to RA…
  • Abstract Number: 1400 • ACR Convergence 2024

    Disease Modifying Anti-rheumatic Drug Use and Association with Survival in Patients with Rheumatoid Arthritis and Newly Diagnosed Lung Cancer

    Varun Nandakumar1, Aaron Baraff2, Alexander Peterson2, Nicholas Smith3, Jennifer Barton4, Ann O'Hare2, Christopher Li5, Noel Weiss3 and Namrata Singh6, 1AIIMS, New Delhi, Delhi, India, 2VA PUGET SOUND SEATTLE, Seattle, WA, 3University of Washington, Seattle, WA, 4VA Portland Health Care System/OHSU, Portland, OR, 5University of Washington, Seattle, 6University of Washington, Bellevue, WA

    Background/Purpose: Despite the significant therapeutic benefits of various disease modifying anti-rheumatic drugs (DMARDs) in RA, concerns remain regarding their safety, particularly their potential impact on…
  • Abstract Number: 1679 • ACR Convergence 2024

    Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study

    Nathanial Eddy1, Jane Buckner2, Paul Emery3, Michael Weinblatt4, Vivian Bykerk5, Andrew Cope6, Gerd Burmester7, Yoshiya Tanaka8, Gustavo Citera9, Peter Nash10, Quentin Dornic11, Peter Schafer12, Sheila Kelly13, Michael Maldonado11 and Jinqi Liu11, 1Bristol Myers Squibb, Princeton, 2Benaroya Research Institute, Seattle, WA, 3University of Leeds, Leeds, United Kingdom, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Hospital For Special Surgery, New York, NY, 6King's College London, London, United Kingdom, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 9Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 10Griffith University, Brisbane, Australia, 11Bristol Myers Squibb, Princeton, NJ, 12Bristol Myers Squibb, BELLE MEAD, NJ, 13Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
  • Abstract Number: 1836 • ACR Convergence 2024

    Transcriptional Changes in the Formation of Tissue Resident Memory T Cells in the Joint

    Yang Yang1, Yusuke Miyashita1, Vitor Aguiar1, Maria Gutierrez-Arcelus1, Kellen Winden2, Peter Nigrovic3 and Margaret Chang1, 1Boston Children's Hospital, Boston, MA, 2Boston Children's Hospital, Boston, MA, 3Boston Children's Hospital, Brookline, MA

    Background/Purpose: Rheumatoid arthritis is a chronic autoimmune disease characterized by joint-specific memory, the phenomenon in which arthritis repeatedly flares in the same joints. We previously…
  • Abstract Number: 1899 • ACR Convergence 2024

    Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

    Tate Johnson1, Yangyuna Yang1, Punyasha Roul2, Joshua Baker3, Gary Kunkel4, Sauer brian5, grant Cannon6, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: People with rheumatoid arthritis (RA) are at an increased risk of heart failure (HF), which is among the most burdensome chronic conditions and a…
  • Abstract Number: 1989 • ACR Convergence 2024

    Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis

    Minerva Nong1, Deanna Jannat-Khah2, Karmela Kim Chan2, Nilasha Ghosh3 and Anne Bass4, 1Hospital for Special Surgery, Tampa, FL, 2Hospital For Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
  • Abstract Number: 2214 • ACR Convergence 2024

    Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3

    Irtza Badar1 and Martin Bergman2, 1Mercy Catholic Medical Center, Philadelphia, PA, 2self, Beach Haven, NJ

    Background/Purpose: To determine and revalidate the definitions of disease flares in patients with rheumatoid arthritis (RA) flares based on the changes in Clinical and Simplified…
  • Abstract Number: 2231 • ACR Convergence 2024

    Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort

    Susan Bartlett1, Orit Schieir2, Marie-France Valois1, Louis Bessette3, Janet Pope4, Gilles Boire5, Carol Hitchon6, Ed Keystone7, Carter Thorne8, Diane Tin8, Glen Hazlewood9, Hugues Allard-Chamard10, Bindee Kuriya11, Vivian Bykerk12 and Clifton Bingham13, and Investigators with the Canadian Early Arthritis Cohort (CATCH), 1Centre for Outcomes Research & Eval, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University of Laval, Quebec City, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Retired, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 9University of Calgary, Calgary, AB, Canada, 10University of Sherbrooke, Sherbrooke, QC, Canada, 11University of Toronto - Toronto, Toronto, ON, Canada, 12Hospital for Special Surgery, New York, NY, 13Johns Hopkins University, Baltimore, MD

    Background/Purpose: Growing evidence suggests that across chronic diseases, patients with co-occurring symptoms of pain, anxiety, and depression (PAD), known as “symptom clusters”, experience variable disease…
  • Abstract Number: 2247 • ACR Convergence 2024

    Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis

    Klára Prajzlerová1, Olga Kryštufková2, Petra Hánová1, Nora Růžičková2, Hana Hulejová1, Jiří Vencovský2, Ladislav Šenolt2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology